Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 41 - 60 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oral Presentation of Phase 2 PREVENT Data at ENDO
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY 18 Financials, Pipeline Progress, and Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Submission of Progeria NDA in 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lambda - Avexitide Succeed in Phase 2; Next Initiation of HDV Phase 3 by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submission of Lonafarnib for Progeria Anticipated in 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of EIGR shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Phase 2 Catalysts in H2:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.